Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial

Published:2022-07 Issue: Volume:169 Page:67-76
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Soo Ross A.,Huat Tan Eng,Hayashi Hidetoshi,Seto Takashi,Lin Chia-Chi,Ou Sai-Hong Ignatius,Kim Dong-Wan,Liu Geoffrey,Abbattista Antonello,Martini Jean-François,Hooi Wong Chew,Toffalorio Francesca,Solomon Benjamin J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Targeting ALK: precision medicine takes on drug resistance;Lin;Cancer Discov.,2017

2. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

3. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncol.,2017

4. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol.,2018

5. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial;Shaw;Lancet Oncol.,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment;Discover Oncology;2024-09-13

2. Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-07-22

3. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study;Lung Cancer;2024-06

4. Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings;BJC Reports;2024-05-01

5. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L);Therapeutic Advances in Medical Oncology;2024-01